


PHARMACEUTICAL 2021

BOMARIN®

BIOMARIN PHARMACEUTICAL INC Rank 89 of 402





PHARMACEUTICAL 2021



BIOMARIN PHARMACEUTICAL INC Rank 89 of 402

The relative strengths and weaknesses of BIOMARIN PHARMACEUTICAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOMARIN PHARMACEUTICAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 80% points. The greatest weakness of BIOMARIN PHARMACEUTICAL INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 161% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,342,219
Cost of Goods Sold	524,272
Intangible Assets	613,470
Liabilities, Current	492,548
Liabilities, Non-Current	114,195
Other Assets	1,859,860
Other Compr. Net Income	-36,303
Other Expenses	-864,950
Other Liabilities	1,135,275
Other Net Income	23,752
Other Revenues	1,860,455
Property and Equipment	1,032,471
Research and Development	628,116
Selling, General and Administrative Expense	737,669

Output Variable	Value in 1000 USD
Assets	5,848,020
Liabilities	1,742,018
Expenses	1,025,107
Revenues	1,860,455
Stockholders Equity	4,106,002
Net Income	859,100
Comprehensive Net Income	840,948
Economic Capital Ratio	208%

